Vizgen logo

Vizgen Funding & Investors

Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The high throughput and resolution and the low cost per cell achieved by the technology will enable a wide range of tissue-scale basic research and development and will be instrumental to efforts to discover and map cell types and states in a range of tissues and organisms.

vizgen.com

Total Amount Raised: $136,200,000

Vizgen Funding Rounds

  • Series C

    $85,200,000

    Series C Investors

    Tao Capital Partners
    David Walt
    Novalis LifeSciences
    Sofina
    Arch Venture Partners
    Blue Water Life Science Advisors
    Northpond Ventures
  • Series B

    $37,000,000

    Series B Investors

    Tao Capital Partners
    Novalis LifeSciences
    David Walt
    Arch Venture Partners
    Northpond Ventures
    Pura Vida Investments
  • Series A

    $14,000,000

    Series A Investors

    Arch Venture Partners
    Northpond Ventures
Funding info provided by Diffbot.